NervGen Pharma Corp. Common stock
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Adam H. Rogers
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1455 Bellevue Avenue, Suite 301 West Vancouver BC Canada V7T 1C3
- IPO Date
- Feb 8, 2021
- CIK
- 0001751912
- Website
- nervgen.com
- Similar Companies
- Business
- NervGen Pharma Corp. (TSX: NGEN) is a clinical-stage biotechnology company focused on developing therapies that reverse neurological damage and restore neurological function in patients with neurodegenerative and neurological disorders. The company offers a pipeline of proprietary therapeutic candidates, including its lead product NVG-291, a peptide drug designed to promote neural repair and plasticity through mechanisms such as enzymatic degradation of inhibitory chondroitin sulfate proteoglycans; preclinical assets targeting amyloid-beta clearance for Alzheimer's disease and remyelination for multiple sclerosis; and exploratory programs in spinal cord injury, peripheral nerve damage, and stroke recovery. NervGen operates primarily in the biopharmaceutical sector, targeting patients and healthcare providers in North America and Europe with treatments for conditions like spinal cord injury, multiple sclerosis, Alzheimer's disease, and peripheral neuropathies. Founded in 2018 and headquartered in Vancouver, British Columbia, Canada, the company recently completed a Phase 1b clinical trial for NVG-291 in chronic spinal cord injury patients in 2024, announced positive data from an investigator-initiated study demonstrating improved sensory function, secured C$15 million in financing in late 2024 to advance Phase 2 trials, and expanded its leadership team with key hires in clinical development and regulatory affairs to support upcoming milestones.[page:company_website]
NervGen Pharma: I Think The Biggest Risks Are Now Behind It
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
NervGen Announces Proposed Public Offering of Securities
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade)
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
NervGen Pharma to Participate at Upcoming Investor Conferences
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium